Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.

We evaluated the ability of human recombinant granulocyte colony-stimulating factor (rhG-CSF) to prevent chemotherapy-induced neutropenia or to accelerate recovery from this complication and thus allow patients to receive full doses of antineoplastic agents on time, according to protocol design. Twenty-seven patients with transitional-cell carcinoma of the urothelium who were undergoing treatment with methotrexate, doxorubicin, vinblastine, and cisplatin were given rhG-CSF (up to 60 micrograms per kilogram of body weight per day) before their first cycle of combination chemotherapy, during the first cycle, or at both points. Treatment with rhG-CSF before chemotherapy resulted in a dose-dependent increase in the absolute neutrophil count. Treatment with rhG-CSF after chemotherapy significantly reduced the number of days (91 percent) per patient on which the absolute neutrophil count was 1000 per microliter or less (P = 0.0039), reduced the number of days (1 vs. 35) on which antibiotics were used to treat fever and neutropenia, and significantly increased the percentage (100 vs. 29 percent) of patients qualified to receive planned chemotherapy on day 14 of the treatment cycle (P = 0.0015). In addition, the incidence of mucositis was significantly decreased (11 vs. 44 percent, P = 0.041), as was its severity. These findings demonstrate that rhG-CSF is a potent stimulus of normal neutrophil proliferation and maturation. In addition, its administration can reduce both the hematopoietic and oral toxicity of chemotherapy.

[1]  J. Griffin,et al.  Acquisition of formyl peptide receptors during normal human myeloid differentiation , 1987 .

[2]  J. Groopman,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. , 1987, The New England journal of medicine.

[3]  E. Liehl,et al.  Recombinant human GM-CSF induces leukocytosis and activates peripheral blood polymorphonuclear neutrophils in nonhuman primates. , 1987, Blood.

[4]  J. Gabrilove,et al.  Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates , 1987, The Journal of experimental medicine.

[5]  A. Gown,et al.  Stromal cells from human long-term marrow cultures, but not cultured marrow fibroblasts, phagocytose horse serum constituents: studies with a monoclonal antibody that reacts with a species-specific epitope common to multiple horse serum proteins. , 1987, Experimental hematology.

[6]  Yu-Chung Yang,et al.  Human IL-3 (multi-CSF): Identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3 , 1986, Cell.

[7]  V. Devita Dose-response is alive and well. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Gabrilove,et al.  Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. , 1986, Science.

[9]  P. Sehgal,et al.  Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF , 1986, Nature.

[10]  J. Gabrilove,et al.  Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells , 1985, The Journal of experimental medicine.

[11]  E. Kawasaki,et al.  Molecular cloning of a complementary DNA encoding human macrophage-specific colony-stimulating factor (CSF-1). , 1985, Science.

[12]  J. Gabrilove,et al.  Distinct differentiation-inducing activities of gamma-interferon and cytokine factors acting on the human promyelocytic leukemia cell line HL-60. , 1985, Cancer research.

[13]  E. Brown,et al.  Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. , 1985, Science.

[14]  N. Geller,et al.  Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. , 1985, The Journal of urology.

[15]  S. Sonis,et al.  Oral Complications of Cancer Chemotherapy , 2011, Developments in Oncology.

[16]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[17]  E. Frei,et al.  Dose: a critical factor in cancer chemotherapy. , 1980, The American journal of medicine.

[18]  P. Lockhart,et al.  Relationship of oral complications to peripheral blood leukocyte and platelet counts in patients receiving cancer chemotherapy. , 1979, Oral surgery, oral medicine, and oral pathology.

[19]  P. Rubin,et al.  The bone marrow organ: the critical structure in radiation-drug interaction. Sir Stanford Cade Memorial lecture. , 1978, International journal of radiation oncology, biology, physics.

[20]  J. Murray,et al.  Life and contributions of David Hume. , 1974, Transplantation proceedings.

[21]  F. Schabel,et al.  Toxicity Studies in Mice Treated with 1-β-d-Arabinofuranosyl-cytosine (ara-C) , 1969 .

[22]  Y. S. Sathe,et al.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. , 1966, Annals of internal medicine.

[23]  W. Dameshek,et al.  Chronic hypoplastic neutropenia. , 1952, The American journal of medicine.

[24]  H. Reimann,et al.  PERIODIC (CYCLIC) NEUTROPENIA, AN ENTITY A COLLECTION OF SIXTEEN CASES , 1949 .